<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03360721</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0060</org_study_id>
    <secondary_id>NCI-2018-01054</secondary_id>
    <secondary_id>2017-0060</secondary_id>
    <nct_id>NCT03360721</nct_id>
  </id_info>
  <brief_title>Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer</brief_title>
  <official_title>A Phase 2, Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Metastatic Prostate Cancer Patients Evaluating a Predetermined Biomarker Signature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well apalutamide and abiraterone acetate work in treating&#xD;
      participants with castration resistant prostate cancer that has spread to other places in the&#xD;
      body (metastatic). Abiraterone acetate and apalutamide may stop the growth of tumor cells by&#xD;
      blocking some of the enzymes needed for cell growth. Immunosuppressive therapy, such as&#xD;
      prednisone, is used to decrease the body's immune response and may improve bone marrow&#xD;
      function. Giving apalutamide, abiraterone acetate, and prednisone may work better in treating&#xD;
      participants with castration resistant prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess the radiographic progression free survival (PFS) of men with metastatic&#xD;
      castration resistant prostate cancer (mCRPC) who are selected for treatment based on positive&#xD;
      biomarker signature.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Safety. II. Composite progression free survival (PFSc) defined by Prostate Cancer Working&#xD;
      Group 2 (PCWG2) (radiographic progression, prostate specific antigen [PSA] progression, or&#xD;
      clinical deterioration).&#xD;
&#xD;
      III. Overall survival. IV. Exploratory biomarker analyses. V. Measures of prostate specific&#xD;
      antigen (PSA) decline and associations with outcome.&#xD;
&#xD;
      VI. Radiologic response by PCWG2 criteria. VII. Measures of circulating tumor cell (CTC) and&#xD;
      conversion to undetectable and/or favorable &lt; 5.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants receive abiraterone acetate orally (PO) once daily (QD), apalutamide PO QD, and&#xD;
      prednisone PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, participants are followed up for up to 16 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    PI Request&#xD;
  </why_stopped>
  <start_date type="Actual">March 6, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From enrollment until radiographic progression, death from any cause, start of other therapy or last follow-up without progression, whichever comes first assessed up to 28 months</time_frame>
    <description>Will be assessed using primary analysis set (PAS). Kaplan-Meier curves will be presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 28 months</time_frame>
    <description>Will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03 with grade and attribution to study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite progression free survival (PFSc)</measure>
    <time_frame>From protocol treatment start until Prostate Cancer Working Group 2 (PCWG2) progression (radiographic progression, PSA progression, or clinical deterioration), death, starting new treatment or last follow-up without PCWG2 progression</time_frame>
    <description>Will be assessed using PAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Baseline until death or last contact, assessed up to 28 months</time_frame>
    <description>Will be assessed using PAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androgen expression signaling</measure>
    <time_frame>Baseline to week 13</time_frame>
    <description>Will be assessed using marker evaluable set (MES). The association between the biomarker and PSA level will be estimated using Spearman's rank correlation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival escape pathway signaling</measure>
    <time_frame>Baseline to week 13</time_frame>
    <description>Will be assessed using MES.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA measurement</measure>
    <time_frame>Up to 28 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Castration-Resistant Prostate Carcinoma</condition>
  <condition>Prostate Adenocarcinoma Without Neuroendocrine Differentiation</condition>
  <condition>Stage IV Prostate Cancer AJCC v8</condition>
  <condition>Stage IVA Prostate Cancer AJCC v8</condition>
  <condition>Stage IVB Prostate Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (abiraterone acetate, apalutamide, prednisone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive abiraterone acetate PO once daily QD, apalutamide PO QD, and prednisone PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (abiraterone acetate, apalutamide, prednisone)</arm_group_label>
    <other_name>CB7630</other_name>
    <other_name>Yonsa</other_name>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (abiraterone acetate, apalutamide, prednisone)</arm_group_label>
    <other_name>ARN 509</other_name>
    <other_name>ARN-509</other_name>
    <other_name>ARN509</other_name>
    <other_name>Erleada</other_name>
    <other_name>JNJ 56021927</other_name>
    <other_name>JNJ-56021927</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (abiraterone acetate, apalutamide, prednisone)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate without&#xD;
             neuroendocrine differentiation or small cell features&#xD;
&#xD;
          -  Presence of metastatic disease that can be biopsied by any methodology applicable&#xD;
&#xD;
          -  Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH)&#xD;
             analogue or orchiectomy (i.e., surgical or medical castration)&#xD;
&#xD;
          -  Serum testosterone level =&lt; 50 ng/dL at the screening visit&#xD;
&#xD;
          -  Progressive disease defined as one or more of the following three criteria (NOTE:&#xD;
             Patients who received an antiandrogen must demonstrate disease progression following&#xD;
             discontinuation of antiandrogen):&#xD;
&#xD;
               -  PSA progression defined by a minimum of two rising PSA levels with an interval of&#xD;
                  &gt;= 1 weeks between each determination. The PSA value at the screening visit&#xD;
                  should be &gt;= 2 ng/mL&#xD;
&#xD;
               -  Soft tissue disease progression as defined by the Response Evaluation Criteria in&#xD;
                  Solid Tumors (RECIST)&#xD;
&#xD;
               -  Bone disease progression defined by two or more new lesions on bone scan&#xD;
&#xD;
          -  Patients previously treated with chemotherapy must have no more than two prior&#xD;
             chemotherapy regimens for the treatment of metastatic prostate cancer&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Serum albumin &gt;= 3.0 g/dL&#xD;
&#xD;
          -  Serum potassium &gt;= 3.5 mmol/L&#xD;
&#xD;
          -  Estimated life expectancy of &gt;= 6 months&#xD;
&#xD;
          -  Able to swallow the study drug and comply with study requirements&#xD;
&#xD;
          -  Willing and able to give informed consent&#xD;
&#xD;
          -  Tumor specimen obtained prior to treatment initiation by interventional radiology&#xD;
             guided biopsy will be interrogated per immunohistochemistry (IHC) and features should&#xD;
             be as follows for a patient to be eligible&#xD;
&#xD;
               -  Overexpression of androgen receptor (AR)-C terminal and AR-N terminal and PTEN&#xD;
                  with lack of ARV7 expression along with and ki67 =&lt;10%&#xD;
&#xD;
               -  No combined RB loss and p53 mutation and&#xD;
&#xD;
               -  No expression of neuroendocrine markers CD56 and chromogranin (all markers&#xD;
                  assessed by standardized IHC protocols)&#xD;
&#xD;
          -  Agrees to use a condom (even men with vasectomies) and another effective method of&#xD;
             birth control if he is having sex with a woman of childbearing potential or agrees to&#xD;
             use a condom if he is having sex with a woman who is pregnant while on study drug and&#xD;
             for 3 months following the last dose of study drug. Must also agree not to donate&#xD;
             sperm during the study and for 3 months after receiving the last dose of study drug&#xD;
&#xD;
               -  The methods must consist of a condom and the use of another barrier method (such&#xD;
                  as a diaphragm or cervical/vault caps) with a spermicidal agent. Your female&#xD;
                  partner can choose to use an intrauterine device or system (intrauterine device&#xD;
                  [IUD] or intrauterine system [IUS]) or use birth control pills, injections, or&#xD;
                  implants instead of a barrier method&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to the study drugs or any of its components&#xD;
&#xD;
          -  Severe, concurrent disease, infection, or co-morbidity that, in the judgment of the&#xD;
             investigator, would make the patient inappropriate for enrollment or other medical&#xD;
             condition that would make prednisone/prednisolone (corticosteroid) use contraindicated&#xD;
&#xD;
          -  Known metastases to the brain&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 1000/uL at the screening visit&#xD;
&#xD;
          -  Platelet count =&lt; 100,000 x 10^9/uL at the screening visit&#xD;
&#xD;
          -  Hemoglobin &lt; 9 g/dL at the screening visit at the screening visit&#xD;
&#xD;
          -  NOTE: patients may not have received any growth factors or blood transfusions within&#xD;
             seven days of the hematologic laboratory values obtained at the screening visit&#xD;
&#xD;
          -  Total bilirubin (Tbili) &gt; 1.5 times the upper limit of normal at the screening visit&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2.5 times the&#xD;
             upper limit of normal at the screening visit&#xD;
&#xD;
          -  Creatinine (Cr) &gt; 2 mg/dL at the screening visit&#xD;
&#xD;
          -  History of another malignancy within the previous 2 years with &gt; 30 % probability of&#xD;
             relapse other than curatively treated non-melanomatous skin cancer&#xD;
&#xD;
          -  Treatment with androgen receptor antagonists (bicalutamide, flutamide, nilutamide),&#xD;
             5-alpha reductase inhibitors (finasteride, dutasteride), estrogens, chemotherapy, or&#xD;
             biologic therapy within 4 weeks of enrollment (day 1 visit)&#xD;
&#xD;
          -  Radiation therapy within 3 weeks (if single fraction of radiotherapy within 2 weeks)&#xD;
             of enrollment (day 1 visit)&#xD;
&#xD;
          -  Planned palliative procedures for alleviation of bone pain such as radiation therapy&#xD;
             or surgery&#xD;
&#xD;
          -  Structurally unstable bone lesions suggesting impending fracture&#xD;
&#xD;
          -  History of seizure or any condition that may increase the patient's seizure risk.&#xD;
             Also, history of loss of consciousness or transient ischemic attack within 12 months&#xD;
             of day 1&#xD;
&#xD;
          -  Clinically significant cardiovascular disease including:&#xD;
&#xD;
               -  Myocardial infarction within 6 months&#xD;
&#xD;
               -  Uncontrolled angina within 6 months&#xD;
&#xD;
               -  Congestive heart failure New York Heart Association (NYHA) class 3 or 4 in the&#xD;
                  past, or history of anthracycline or anthracenedione (mitoxantrone) treatment,&#xD;
                  unless a screening echocardiogram or multi-gated acquisition scan (MUGA)&#xD;
                  performed within three months results in a left ventricular ejection fraction&#xD;
                  that is &gt;= 45%&#xD;
&#xD;
               -  History of clinically significant ventricular arrhythmias (e.g., ventricular&#xD;
                  tachycardia, ventricular fibrillation, torsades de pointes)&#xD;
&#xD;
               -  Prolonged corrected QT interval by the Fridericia correction formula (QTcF) on&#xD;
                  the screening electrocardiogram (ECG) &gt; 470 msec&#xD;
&#xD;
               -  History of Mobitz II second degree or third degree heart block without a&#xD;
                  permanent pacemaker in place&#xD;
&#xD;
               -  Hypotension (systolic blood pressure &lt; 86 millimeters of mercury or bradycardia&#xD;
                  with a heart rate of &lt; 50 beats per minute on any ECG taken at the screening&#xD;
                  visit&#xD;
&#xD;
               -  Bradycardia with a heat rate of &lt; 50 beats per minutes in the screening ECG,&#xD;
                  unless pharmaceutically induced and reversible&#xD;
&#xD;
               -  Chronically uncontrolled hypertension as indicated by consistently elevated&#xD;
                  resting blood pressure (systolic blood pressure &gt; 170 mmHg or diastolic blood&#xD;
                  pressure &gt; 105 mmHg) during screening&#xD;
&#xD;
          -  Have used or plan to use from 30 days prior to enrollment (day 1 visit) through the&#xD;
             end of the study the following medications known to lower the seizure threshold:&#xD;
&#xD;
               -  Aminophylline/theophylline&#xD;
&#xD;
               -  Atypical antipsychotics (e.g., clozapine, olanzapine, risperidone, ziprasidone)&#xD;
&#xD;
               -  Bupropion&#xD;
&#xD;
               -  Insulin&#xD;
&#xD;
               -  Lithium&#xD;
&#xD;
               -  Pethidine&#xD;
&#xD;
               -  Phenothiazine antipsychotics (e.g., prochlorperazine [compazine], chlorpromazine,&#xD;
                  mesoridazine, thioridazine)&#xD;
&#xD;
               -  Tricyclic and tetracyclic antidepressants (e.g., amitriptyline, desipramine,&#xD;
                  doxepin, imipramine, maprotiline, mirtazapine)&#xD;
&#xD;
          -  Prior use of ketoconazloe, enzalutamide, abiraterone or apalutamide or participation&#xD;
             in a previous clinical trial of ketoconazloe,enzalutamide, abiraterone or apalutamide&#xD;
             unless within the neoadjuvant setting&#xD;
&#xD;
          -  Use of an investigational agent within 4 weeks of enrollment (day 1)&#xD;
&#xD;
          -  Gastrointestinal disorder affecting absorption (e.g., gastrectomy)&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to enrollment (day 1)&#xD;
&#xD;
          -  History of significant bleeding disorder unrelated to cancer, including:&#xD;
&#xD;
               -  Diagnosed congenital bleeding disorders (e.g., von Willebrand's' disease)&#xD;
&#xD;
               -  Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor&#xD;
                  VIII antibodies)&#xD;
&#xD;
               -  History of gastrointestinal (GI) bleeding within one year&#xD;
&#xD;
          -  Known active or symptomatic viral hepatitis or chronic liver disease&#xD;
&#xD;
          -  Known history of pituitary or adrenal dysfunction&#xD;
&#xD;
          -  Baseline moderate and severe hepatic impairment (Child Pugh class B &amp; C)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bagi Jana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Official Website</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2017</study_first_posted>
  <last_update_submitted>February 21, 2021</last_update_submitted>
  <last_update_submitted_qc>February 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

